HCA
PTCT icon

Harbor Capital Advisors’s PTC Therapeutics PTCT Stock Holding History

Harbor Capital Advisors’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-39,005
Closed -$2.96M – 1433
2025
Q4 		$2.96M Sell
39,005
-10,595
-21% -$770K 0.23% 99
2025
Q3 		$3.04M Buy
49,600
+833
+2% +$43.4K 0.24% 92
2025
Q2 		$2.38M Buy
48,767
+8,042
+20% +$382K 0.1% 261
2025
Q1 		$2.08M Sell
40,725
-11,891
-23% -$593K 0.09% 279
2024
Q4 		$2.38M Sell
52,616
-1,398
-3% -$59.8K 0.1% 249
2024
Q3 		$2M Buy
54,014
+6,634
+14% +$222K 0.09% 300
2024
Q2 		$1.45M Buy
47,380
+13,326
+39% +$432K 0.11% 267
2024
Q1 		$991K Sell
34,054
-4,329
-11% -$121K 0.13% 217
2023
Q4 		$1.06M Buy
38,383
+9,072
+31% +$207K 0.2% 122
2023
Q3 		$657K Sell
29,311
-1,457
-5% -$54.2K 0.14% 181
2023
Q2 		$1.25M Buy
+30,768
New +$1.51M 0.25% 98

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Harbor Capital Advisors's PTCT Position: Q1 2026 in Review

Harbor Capital Advisors sold out of PTC Therapeutics (PTCT) in Q1 2026, closing a stake of 39,005 shares — an estimated $2.96M sold.

Harbor Capital Advisors first reported a position in PTCT in Q2 2023 and held it in 11 quarters. The position peaked at $3.04M in Q3 2025. 352 funds tracked by Wall St. Rank hold PTCT as of Q1 2026.

  • Harbor Capital Advisors reported no remaining PTC Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Harbor Capital Advisors sold 39,005 PTC Therapeutics shares in Q1 2026, an estimated $2.96M.
  • Harbor Capital Advisors first reported a position in PTC Therapeutics in Q2 2023 and held it in 11 quarters.
  • Harbor Capital Advisors's PTC Therapeutics position peaked at $3.04M in Q3 2025.
  • 352 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2026.

Based on Harbor Capital Advisors's 13F filing for Q1 2026, filed 28 Apr 2026.